Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money

79% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

Tricks of the trade

How to Day Trade Stocks & Indices

Learn how to:

  • Place your first trade
  • Identify 9 chart patterns
  • Pro strategies step-by-step

You'll also receive our newsletter and other Opto emails in accordance with our privacy policy.

Opportunities

Invest in biotech

13 Biotech Stocks to Watch in 2020

  • 5 high-growth opportunities
  • 6 key price levels
  • 7 market disruptors

+ You'll also receive our newsletter and other Opto emails in accordance with our privacy policy.

The Biotech Breakout

+443%

One stock's return in 2019

$729bn

IBB index predicted valuation by 2025

+370%

One stock's growth since its IPO in 1995

$280bn

One biotech behemoth's mammoth valuation

+57%

Vertex Pharmaceuticals' 5-year return

+26%

IBB3-month rally from October to December 2019

-36%

Nasdaq Biotech Index loss following 2015 bubble

Why the breakout?

Learn why biotech stocks started soaring, and which fundamentals have set the foundation for long-term growth

Who to watch?

Discover the market disruptors in this high-growth sector, as we identify the companies at the cutting edge of biotech innovation

How to trade?

Whether it's individual stocks or ETFs, we explore the variety of ways traders can get exposure to this exciting sector

ebook preview

Breakout biotech stocks, under the microscope

We explain the surging share prices, identify the disruptors set to topple traditional heavyweights, and highlight the current opportunities in this high-growth sector

+$150 billion

Free cash flow generated per year by top 20 biopharma firms

175%

Blueprint Medicines share price return since IPO

127 deals

Number of biotech company acquisitions in 2019

The SPDR S&P Biotech ETF has outpaced both the Health Care Select Sector SPDR fund and S&P 500 since 2017

We are OPTO

Trading intelligence for the serious trader

OPTO started with a simple idea: that markets cannot truly be understood through numbers alone. Every company, investor and executive plays a role in shaping the market from one day to the next. By telling their stories and understanding what drives them, OPTO’s analysis provides a more holistic picture of what truly moves markets – and what those cold, hard numbers really mean.

Newsletter

13,000+ subscribers

Website

60,000+ monthly visits

Social media

Engaging online community

Quarterly magazine

Global circulation of 25,000

Free industry reports

7,000+ downloads

Exclusive events

London-based with industry experts

Leveraged ETFs are complex financial instruments that carry significant risks. Certain leveraged ETF's are only considered appropriate for experienced traders